A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer
Recruiting now · Phase 1
Conditions studied: Breast Cancer, Breast Neoplasm, Breast Cancer Stage IV
In brief
A Phase 1, open-label, dose-escalation clinical trial of MBQ-167 in participants with advanced Breast Cancer for whom Standard of Care (SOC) has failed or has proven intolerable.
Key facts
- Study ID
- NCT06075810
- Run by
- MBQ Pharma
- People needed
- 48
- Starts
- 2023-11-09
- Expected to finish
- 2025-10-31
- Last updated by the study team
- 2024-12-12
Who can join
Age: 21 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Precision Next Gen Oncology & Research Center — Beverly Hills, California, United States (enrolling)
- Florida Cancer Specialists / Sarah Cannon Research Institute / SCRI — Sarasota, Florida, United States (enrolling)
- Sarah Cannon Research Institute/SCRI — Nashville, Tennessee, United States (enrolling)
- FDI Clinical Research — San Juan, Puerto Rico (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.